Business Wire (Wed, 6:30PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
774 people get SNTA articles and Market Currents by email alert.
Get email alerts on SNTA »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (Apr 30, 2013)
-
Business Wire (Apr 16, 2013)
-
Business Wire (Apr 5, 2013)
-
-
Business Wire (Mar 14, 2013)
-
Business Wire (Mar 13, 2013)
-
-
-
-
Business Wire (Feb 25, 2013)
-
Business Wire (Feb 11, 2013)
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
Synta Readying 2 Key Lung Cancer TrialsLen Zehr • Wed, Apr 20, 2011 -
Putting a Price Tag on Synta's Lead Drug ActivitiesOhad Hammer • Sun, Mar 20, 2011
-
-
-
-
Evaluating Synta Pharmaceuticals' CashflowBrian Orelli • Mon, Mar 26, 2007 -
Recent IPO Synta Pharma Sees Strong Insider BuyingRichard Shonfeld • Tue, Feb 27, 2007
-
-
-
-
-
-
-
-
-
-
5 Healthcare Companies With Significant Recent Insider Buying (Part IV)Markus Aarnio • Wed, Nov 14, 2012
-
Investments In The Fight Against Cancer: The Analysts' ChoicesGlen S. Woods • Mon, Nov 5, 2012 -
-
-
-
-
5 Highly Shorted Small-Caps With Strong Insider And Institutional BuyingKapitall • Tue, Sep 18, 2012
-
-
-
-
Insiders Love These 10 Outperforming Healthcare StocksKapitall • Tue, Jul 10, 2012
-
Synta Pharmaceuticals Corp. Q1 2010 Earnings Call TranscriptTue, May 4, 2010
-
Synta Pharmaceuticals Corp. Q3 2009 Earnings Call TranscriptWed, Nov 4, 2009
-
Synta Pharmaceuticals Corp. Q3 2008 Earnings Call TranscriptThu, Nov 13, 2008
-
Synta Pharmaceuticals Corp. Q2 2008 Earnings Call TranscriptTue, Sep 2, 2008
-
Synta Pharmaceuticals Corp. Q1 2008 Earnings Call TranscriptTue, May 27, 2008
-
Synta Pharmaceuticals Corp. Q4 2007 Earnings Call TranscriptThu, Mar 20, 2008
-
Business Wire (Wed, 6:30PM)
-
Business Wire (Apr 30, 2013)
-
Business Wire (Apr 16, 2013)
-
Business Wire (Apr 5, 2013)
-
Business Wire (Mar 14, 2013)
-
Business Wire (Mar 13, 2013)
-
Business Wire (Feb 25, 2013)
-
Business Wire (Feb 11, 2013)
-
Business Wire (Dec 13, 2012)
-
Business Wire (Dec 12, 2012)
-
Business Wire (Nov 27, 2012)
-
Business Wire (Nov 26, 2012)
-
Business Wire (Nov 9, 2012)
-
Business Wire (Nov 7, 2012)
-
Business Wire (Nov 6, 2012)
-
Business Wire (Oct 24, 2012)
-
Business Wire (Sep 18, 2012)
SNTA vs. ETF Alternatives
Company Description
Currently, there's no company description for SNTA.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Wednesday, May 8, 12:53 PM
Midday top 10 gainers: TRMD +68%. SYNM +35%. AFFY +35%. ALXA +25%. CSPI +21%. PSE +21%. NBG +20%. WBMD +18%. SCOK +17%. EA +16%.
Midday top 10 losers: FIO -25%. OCLR -23%. LIOX -18%. VCLK -17%. AXLL -16%. OCLS -15%. BTH -15%. SALM -13%. ACFC -12%. SNTA -12%. Comment! [On the Move] -
Tuesday, May 7, 12:52 PM
Midday top 10 gainers: FSGI +28%. ARCI +27%. ININ +18%. MELI +18%. NLS +18%. PRTS +18%. REED +16%. PODD +14%. LAS +12%. MKTG +12%.
Midday top 10 losers: DCO -27%. RKUS -25%. GNK -24%. CUTR -23%. ARUN -22%. SNTA -15%. AMRI -12%. PIKE -12%. TA -12%. PTRY -11%. Comment! [On the Move] - Tuesday, April 30, 6:57 AM Synta Pharmaceuticals (SNTA): Q1 EPS of -$0.30 misses by $0.03. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, March 14, 8:00 AM Synta Pharmaceuticals (SNTA): Q4 EPS of -$0.29 misses by $0.03. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, December 13, 2012, 12:24 PM Synta Pharmaceuticals (SNTA +3.6%) trades up after saying it's entered into stock purchase agreements with members of its Board and various institutional investors to sell 7M shares of its common stock in an issuer directed, registered direct offering. Shares were priced at $8.60, yesterday's closing bid price. Gross proceeds from the sale were approximately $60M. Comment! [Healthcare, On the Move]
-
Monday, November 12, 2012, 5:45 PM
After-hours top gainers, as of 5:15 p.m.: SNTA +19.8%. IQNT +18.7%. LPH +10.2%. TSPT +8.9%. CSOD +8.1%.
After-hours top losers: INFI -8.6%. SCLN -5.5%. EVER -4.4%. GME -4.1%. MWE -3.7%. Comment! [On the Move] -
Monday, October 1, 2012, 12:45 PM
Midday top 10 gainers: CRDN +43%. FONR +34%. BIOF +19%. VSR +17%. MTG +16%. SNTA +16%. VSNT +15%. PATK +14%. MGI +12%. SFUN +12%.
Top 10 Losers: NC -65%. TYC -49%. GMAN -24%. BYFC -17%. THLD -17%. PPHM -16%. GNI -11%. OCZ -10%. ROSG -10%. CYTX -8%. 1 Comment [On the Move] - Monday, October 1, 2012, 10:39 AM Synta Pharmaceuticals (SNTA +11.6%) pops after reporting encouraging results from its Phase 2b Galaxy trial of ganetespib - the company's lead Hsp90 inhibitor - as second-line treatment for advanced non-small cell lung cancer. The company says test results showed good tolerability for the combination of ganetespib and docetaxel as well as meaningful improvements in overall survival in adenocarcinoma patients receiving the drug combination. Comment! [Healthcare, On the Move]
- Thursday, June 28, 2012, 12:10 PM Synta Pharmaceuticals (SNTA) -30% and extending its losses from AH trading yesterday after disclosing mixed interim results from a Phase IIb/III trial of its ganetespib treatment for lung cancer. Synta is assessing the drug in combination with docetaxel, a leading chemotherapy. Comment! [Healthcare, On the Move]
-
Thursday, June 28, 2012, 9:05 AM
Premarket gainers: SURG +41%. OREX +10%. AAV +5%.
Losers: ANTH -63%. SNTA -25%. VRTX -13%. BCS -12%. RBS -11%. FDO -7%. DB -5%. Comment! [On the Move] - Wednesday, June 27, 2012, 4:27 PM Synta Pharmaceuticals (SNTA) gets hit hard in post-session trading after announcing mixed interim results from its Phase 2b study of ganetespib, a treatment for advanced non-small cell lung cancer. The company says it plans to proceed to Phase 3. Shares -17% AH. Comment! [Healthcare, On the Move]
- Monday, June 4, 2012, 1:29 PM BMO Capital adds to Synta Pharmaceuticals (SNTA +3%) updraft, upgrading it Outperform ahead of its full GALAXY data release and a more constructive view of ganetespib's potential for success. Ther firm also raises its price target to $10 from $5. Comment! [Healthcare, On the Move]
- Monday, June 4, 2012, 11:29 AM Synta Pharmaceuticals (SNTA +2.8%) gains after saying a study of ganetespib, its lead drug candidate, showed positive results as a treatment for oncologic indications, including a reduced rate of ocular toxicity. SNTA's primary research focus is on treatments for severe conditions such as cancer and chronic inflammatory diseases. Comment! [Healthcare, On the Move]
- Monday, May 21, 2012, 4:19 PM Syntha Pharmaceuticals (SNTA +7.9%) gets a pop today after Jefferies initiated the shares with a Buy rating and a price target of $7. Comment! [Healthcare]
- Tuesday, February 7, 2012, 5:25 PM Small biotechs are almost always highly speculative, so it's essential that any investor who seeks to venture into those murky waters start with informed research of the sort analyst Ohad Hammer provides in his overview of five biotechs to watch: EXEL, CLDX, SGEN, ARRY, SNTA. (h/t Mick Weinstein) Comment! [Healthcare, Quick Ideas]
- Thursday, January 5, 2012, 5:09 PM Synta Pharmaceuticals (SNTA) announces a secondary offering for an undisclosed amount of shares. Jefferies is acting as sole book-running manager. Shares -11.5% AH. Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Joshua Hayes
Big Wave Trading Portfolio Update And Top Current Holdings http://bit.ly/LEAhD2 SNTA FU MAGS VRNM BVSN PHMD AVD ANGI - View all 0 replies
-
- View all 5 replies
-
tuliptown: am long as well. What does the HUGE volume down mean to you? Who were the weak hands leaving and who are buying? agree data was good. -
-
TruffelPig
SNTA: I did read the data - they were actually pretty good; progression free time at least doubled, in some groups tripled - View all 3 replies
-
TruffelPig: Something similar happened to ECYT end of last year - the "expert" investors also sold and were WRONG.
-
TruffelPig: As a biochemist I pressed the buy button today! Price target $10 in the next 12 month. Good story.
-
- View all 0 replies
-
Jim Van Meerten
SNTA - 72% Barchart technical buy signal - 12 new highs and up 49.68% in the past year 0 Relative strength Index 72.23% - View all 1 replies
-
-
- View all 0 replies
LATEST REPLIES
-
- View all 5 replies
-
tuliptown: am long as well. What does the HUGE volume down mean to you? Who were the weak hands leaving and who are buying? agree data was good.
-
-
TruffelPig
SNTA: I did read the data - they were actually pretty good; progression free time at least doubled, in some groups tripled - View all 3 replies
-
TruffelPig: Something similar happened to ECYT end of last year - the "expert" investors also sold and were WRONG.
-
TruffelPig: As a biochemist I pressed the buy button today! Price target $10 in the next 12 month. Good story.
-
Jim Van Meerten
SNTA - 72% Barchart technical buy signal - 12 new highs and up 49.68% in the past year 0 Relative strength Index 72.23% - View all 1 replies
-
-
Todd Theman
Looking for an entry point into SNTA. Is $4 reasonable? Looking for a bump in advance of ASCO this summer. - View all 1 replies
-
PYRAMIDHUNT: An insider bought $5,000,000 of shares at $4.40 just a couple months ago.
-
The Scientist
Market potential for SNTA ganetespib is ridiculous. If it works in half the cancers they are studying, $10B+ potential. - View all 8 replies
-
-
The Scientist: I am a MD, PhD. I used to spend all my time in a molecular biology lab. Now I practice medicine.